FDA Approves OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — ScieGen Pharmaceuticals Inc

# FDA Approves Generic Olmesartan Medoxomil and Hydrochlorothiazide Combination ScieGen Pharmaceuticals Inc received FDA approval for a generic version of olmesartan medoxomil and hydrochlorothiazide, a combination antihypertensive therapy, which is expected to increase price competition in the blood pressure management market and improve patient access to this commonly prescribed treatment. The approval of the fixed-dose combination generic could capture significant market share from brand-name alternatives, particularly benefiting insurers and patients seeking cost-effective hypertension management options.